Key Details
Price
$181.86Annual ROE
12.78%Beta
1.09Events Calendar
Next earnings date:
Jan 31, 2025Recent quarterly earnings:
Nov 06, 2024Recent annual earnings:
Nov 06, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Feb 28, 2006Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
WARREN, N.J., Dec. 23, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) has announced today that their CEO, Matthew B.
Everyone is aware of how artificial intelligence (AI) and wireless digital technologies are becoming more important in our everyday lives. However, many people may not realize the significant impact these changes are having on the manufacturing sector and how an industrial software company like PTC is involved in this transformation.
If it gets the green light, vatiquinone will be the first and only approved treatment for children with Friedreich ataxia (FA). This marks PTC's fourth application for approval submitted to the FDA in 2024. On December 19, 2024, PTC Therapeutics, Inc. announced that they have submitted the New Drug Application (NDA) for vatiquinone to treat both children and adults with FA.
WARREN, N.J., Dec. 17, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that on December 13, 2024, it granted non-statutory stock options for a total of 1,725 shares of its common stock and 5,060 restricted stock units (RSUs) to eight new employees. Each RSU will convert into one share of common stock once it vests.
BOSTON, Dec. 9, 2024 /PRNewswire/ -- PTC (NASDAQ: PTC) has announced the appointment of Robert Dahdah as Executive Vice President and Chief Revenue Officer. Dahdah previously worked at Microsoft as the Corporate Vice President for Global Healthcare and Life Sciences.
PTC has teamed up with Microsoft and Volkswagen to create an AI Copilot called Codebeamer, which aims to make product development easier.
A collaboration has been formed between industry leaders to enhance the use of generative AI in manufacturing. The Codebeamer Copilot is designed to make managing requirements easier during product development, with a beta version expected to launch in early 2025. This tool will help software engineers work more effectively by allowing them to create, manage, test, and validate product requirements.
On Monday, PTC Therapeutics (PTCT) saw its shares rise by 16% after the company revealed a collaboration and licensing agreement worth almost $2 billion with Novartis (NVS).
On Monday, PTC Therapeutics announced that it has signed a licensing agreement with a division of Novartis AG worth up to $1.9 billion. This deal is for their experimental medication aimed at treating a rare neurological condition.
PTC Therapeutics will receive $1 billion in cash upon closing a deal with Novartis Pharmaceuticals for its Huntington's disease program, PTC518. They could earn up to $1.9 billion through various development and sales milestones, and will also share profits and royalties from sales. Novartis will take over global development and commercial responsibilities after the current study is completed, and PTC will hold a conference call on December 2, 2024, at 8:30 am EST.
FAQ
- What is the primary business of PTC?
- What is the ticker symbol for PTC?
- Does PTC pay dividends?
- What sector is PTC in?
- What industry is PTC in?
- What country is PTC based in?
- When did PTC go public?
- Is PTC in the S&P 500?
- Is PTC in the NASDAQ 100?
- Is PTC in the Dow Jones?
- When was PTC's last earnings report?
- When does PTC report earnings?
- Should I buy PTC stock now?